Shares of Xencor Inc. (NASDAQ:XNCR) have earned an average recommendation of “Buy” from the eight ratings firms that are covering the firm. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $27.00.

A number of brokerages recently weighed in on XNCR. Leerink Swann reiterated a “buy” rating and set a $26.00 price objective on shares of Xencor in a report on Thursday, November 3rd. Wedbush reiterated an “outperform” rating and set a $27.00 price objective on shares of Xencor in a report on Monday, September 12th. Piper Jaffray Cos. initiated coverage on shares of Xencor in a report on Tuesday, October 4th. They issued an “overweight” rating and a $35.00 price target for the company. Zacks Investment Research lowered shares of Xencor from a “buy” rating to a “hold” rating in a report on Tuesday, November 8th. Finally, TheStreet lowered shares of Xencor from a “hold” rating to a “sell” rating in a report on Tuesday, November 8th.

Shares of Xencor (NASDAQ:XNCR) opened at 22.71 on Thursday. Xencor has a one year low of $9.89 and a one year high of $26.50. The stock has a market cap of $934.24 million, a PE ratio of 23.27 and a beta of 2.20. The company has a 50-day moving average of $22.09 and a 200 day moving average of $18.68.

In related news, Director Bruce L. A. Carter sold 3,400 shares of the business’s stock in a transaction that occurred on Monday, August 15th. The shares were sold at an average price of $22.67, for a total transaction of $77,078.00. Following the completion of the transaction, the director now owns 10,000 shares in the company, valued at approximately $226,700. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder John S. Stafford III sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, August 15th. The stock was sold at an average price of $23.06, for a total transaction of $230,600.00. The disclosure for this sale can be found here. 4.03% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. JPMorgan Chase & Co. raised its position in Xencor by 106.5% in the second quarter. JPMorgan Chase & Co. now owns 288,950 shares of the biopharmaceutical company’s stock valued at $5,487,000 after buying an additional 149,050 shares during the period. Oxford Asset Management raised its position in Xencor by 300.6% in the second quarter. Oxford Asset Management now owns 367,101 shares of the biopharmaceutical company’s stock valued at $6,971,000 after buying an additional 275,470 shares during the period. PNC Financial Services Group Inc. raised its position in Xencor by 3.2% in the second quarter. PNC Financial Services Group Inc. now owns 66,126 shares of the biopharmaceutical company’s stock valued at $1,256,000 after buying an additional 2,062 shares during the period. EAM Investors LLC purchased a new position in Xencor during the second quarter valued at approximately $1,281,000. Finally, DekaBank Deutsche Girozentrale raised its position in Xencor by 24.1% in the second quarter. DekaBank Deutsche Girozentrale now owns 23,700 shares of the biopharmaceutical company’s stock valued at $439,000 after buying an additional 4,600 shares during the period. Hedge funds and other institutional investors own 68.15% of the company’s stock.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. Its segment is related to the development of pharmaceutical products. It uses its XmAb technology platform to create antibody product candidates designed to treat autoimmune and allergic diseases, cancer and other conditions.

5 Day Chart for NASDAQ:XNCR

Receive News & Stock Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related stocks with our FREE daily email newsletter.